Cipla Limited has announced its audited consolidated financial results for quarter and full year ended March 31, 2019

Key highlights of the quarter and year

Continued growth momentum in private market [non-tender] segments continues across India, South Africa and key Emerging Markets

US business - New launches drive significant growth

• Q4: 41% YoY and 38% QoQ growth
• FY19: 18% YoY growth

Umang Vohra MD and Global CEO, Cipla Ltd said, “FY’19 ended on a strong note for Cipla. While our home markets of India and South Africa continued to lead the way, our US business established robust base growth from differentiated direct-to-market launches. Our planned build-up of respiratory pipeline in the US remains on track. Challenges in the tender businesses and certain volatile markets played out as guided previously. Most importantly, in FY’19, we made important strides in broadening our offerings to patients around the world through health campaigns, innovative products, strategic acquisitions and digital healthcare solutions. From a sustainable growth and direction perspective, we are well-poised for FY20.”

India

• Cipla continued its outperformance in FY19; grew by 11.2% vs market growth of 10.5%
• Strong execution supported by superior prescription generation and market beating growth across key therapies; in-licensed products ramping up
• Chronic therapies: Cipla became the 2nd biggest player growing over 18% vs market growth of 13%
• Strategic partnership with LG Life Sciences for Women Health Portfolio